Home›Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate

Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate

Also known as: Stribild

Cytochrome P450 3A InhibitorHuman Immunodeficiency Virus Integrase Strand Transfer InhibitorHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Route: Oral

Check Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate Interactions →
39 interactions on record⛔ Black Box Warning

Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate has 39 known drug interactions based on U.S. FDA drug labeling data. Of these, 5 are contraindicated combinations that should be avoided entirely. Notable interactions include combinations with Alfuzosin, Lovastatin, Midazolam. Patients taking Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total
39
Contraindicated
5
Moderate
6

Contraindicated (5)

Moderate (6)

Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate + Midazolam⛔Contraindicated

Use of PDE-5 inhibitors for erectile dysfunction: The below PDE-5 inhibitors can be used along with increased monitoring for PDE-5-inhibitor associated adverse events: Sildenafil at a single dose not exceeding 25 mg in 48 hours, or Tadalafil at a single dose not exceeding 10 mg in 72 hours, or Vardenafil at a single dose not exceeding 2.5 mg in 72 hours Sedative/hypnotics: midazolam (oral), triazolam ↑ midazolam ↑ triazolam Coadministration with triazolam or orally administered midazolam is contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression. Triazolam and orally administered midazolam are extensively metabolized by CYP3A. Coadministration of triazolam or orally administered midazolam with STRIBILD may cause large increases in the concentrations of these benzodiazepines.

Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate + Triazolam⛔Contraindicated

Use of PDE-5 inhibitors for erectile dysfunction: The below PDE-5 inhibitors can be used along with increased monitoring for PDE-5-inhibitor associated adverse events: Sildenafil at a single dose not exceeding 25 mg in 48 hours, or Tadalafil at a single dose not exceeding 10 mg in 72 hours, or Vardenafil at a single dose not exceeding 2.5 mg in 72 hours Sedative/hypnotics: midazolam (oral), triazolam ↑ midazolam ↑ triazolam Coadministration with triazolam or orally administered midazolam is contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression. Triazolam and orally administered midazolam are extensively metabolized by CYP3A. Coadministration of triazolam or orally administered midazolam with STRIBILD may cause large increases in the concentrations of these benzodiazepines.

Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate + Tenofovirℹ️Unknown

7.4 Drugs Affecting Renal Function Because emtricitabine and tenofovir, components of STRIBILD, are primarily excreted by the kidneys by a combination of glomerular filtration and active tubular secretion, coadministration of STRIBILD with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of emtricitabine, tenofovir, and other renally eliminated drugs and this may increase the risk of adverse reactions. Hepatitis C Antiviral Agents: ledipasvir/sofosbuvir sofosbuvir/velpatasvir sofosbuvir/velpatasvir/voxilaprevir ↑ tenofovir The safety of increased tenofovir concentrations in the setting of HARVONI ® (ledipasvir/sofosbuvir) and STRIBILD has not been established. Patients receiving STRIBILD concomitantly with EPCLUSA ® (sofosbuvir/velpatasvir) or VOSEVI ® (sofosbuvir/velpatasvir/voxilaprevir) should be monitored for adverse reactions associated with tenofovir disoproxil fumarate.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.